Now we walk through a scenario that integrates everything from the previous stages. A person with opioid use disorder walks past the corner where they used to buy. They feel a wave of craving. What is happening in their brain?
The visual scene reaches the occipital cortex. Patterns of light from the street, the buildings, the corner, register and decompose into edges, shapes, motion, color. So far this is just sensory processing. Nothing about this signal yet says danger or reward.
The temporal lobe recognizes the scene. The combination of features matches a stored representation: this is the corner where I used to buy. Recognition is not just visual; it includes the spatial layout, the time of day, the smell of the place, the sounds. The patient knows where they are.
The hippocampus retrieves the associated memory. The corner is not just a location; it is a node in a network of memories. The rush. The relief. The companions. The ritual. The hippocampus is doing its job of indexing — pulling these associations into working memory now that the cue has appeared.
The amygdala fires. Through years of pairing, the amygdala has tagged this corner as a high-salience cue. The tag fires now, broadcasting this matters to the rest of the brain. Adrenergic outflow rises. Heart rate climbs. Attention narrows.
The VTA fires dopamine into the nucleus accumbens. The mesolimbic pathway responds to the cue by anticipating reward. This is the prediction error signal that we met in Stage 1 — the cue predicts the reward, so dopamine fires before any drug has been taken. The patient feels this as want, an urgent pull toward the corner.
The prefrontal cortex attempts to inhibit. The patient remembers their treatment plan, their family, their commitment to recovery, the negative consequences of past use. The PFC tries to override the limbic signal. But the PFC is metabolically expensive, and chronic substance use has weakened its top-down control over limbic structures. The accumbens is fired up; the PFC is trying to push back; the balance is precarious.
What happens next depends on the strength of each side. If the PFC wins, the patient walks past the corner and the craving slowly dissipates. If the limbic system wins, the patient turns toward the corner. This is craving — not as a moral failure, but as a mechanistic cascade through circuits we have already met.
The pharmacologic intervention is buprenorphine, a partial mu-opioid agonist. It occupies the opioid receptors, dampens the craving and prevents withdrawal, and produces a ceiling effect on its own action that prevents the euphoric surge that drives the cycle. Naltrexone, a mu-opioid antagonist, blocks the receptor entirely; if the patient uses while on naltrexone, the opioid simply does not work.
Both medications are evidence-based, both substantially reduce overdose and relapse, and both work at the molecular level we discussed in Stage 9. The framework you have built lets you see the same patient at three levels simultaneously: as a human being who has walked toward a corner, as a circuit cascade rolling through their brain, as a molecular system that can be modified by precise pharmacologic intervention.